Andrew Johnston1, Xianying Xing2, Liza Wolterink2, Drew H Barnes2, ZhiQiang Yin3, Laura Reingold2, J Michelle Kahlenberg4, Paul W Harms5, Johann E Gudjonsson2. 1. Department of Dermatology, University of Michigan, Ann Arbor, Mich. Electronic address: andjoh@med.umich.edu. 2. Department of Dermatology, University of Michigan, Ann Arbor, Mich. 3. Department of Dermatology, University of Michigan, Ann Arbor, Mich; Department of Dermatology, First Affiliated Hospital of Nanjing Medical University, Nanjing, China. 4. Department of Rheumatology, University of Michigan, Ann Arbor, Mich. 5. Department of Dermatology, University of Michigan, Ann Arbor, Mich; Department of Pathology, University of Michigan, Ann Arbor, Mich.
Abstract
BACKGROUND: Generalized pustular psoriasis (GPP) is a rare, debilitating, and often life-threatening inflammatory disease characterized by episodic infiltration of neutrophils into the skin, pustule development, and systemic inflammation, which can manifest in the presence or absence of chronic plaque psoriasis (PV). Current treatments are unsatisfactory and warrant a better understanding of GPP pathogenesis. OBJECTIVE: We sought to understand better the disease mechanism of GPP to allow improved targeted therapies. METHODS: We performed a gene expression study on formalin-fixed paraffin-embedded GPP (n = 28) and PV (n = 12) lesional biopsies and healthy control (n = 20) skin. Differential gene expression was analyzed using gene ontology and enrichment analysis. Gene expression was validated with quantitative RT-PCR and immunohistochemistry, and a potential disease mechanism was investigated using primary human cell culture. RESULTS: Compared with healthy skin, GPP lesions yielded 479 and PV 854 differentially expressed genes, respectively, with 184 upregulated in both diseases. We detected significant contributions of IL-17A, TNF, IL-1, IL-36, and interferons in both diseases; although GPP lesions furnished higher IL-1 and IL-36 and lower IL-17A and IFN-γ mRNA expression than PV lesions did. We detected prominent IL-36 expression by keratinocytes proximal to neutrophilic pustules, and we show that both neutrophils and neutrophil proteases activate IL-36. Suggesting another mechanism regulating IL-36 activity, the protease inhibitors serpin A1 and A3, which inhibit elastase and cathepsin G, respectively, were upregulated in both diseases and inhibited activation of IL-36. CONCLUSIONS: Our data indicate sustained activation of IL-1 and IL-36 in GPP, inducing neutrophil chemokine expression, infiltration, and pustule formation, suggesting that the IL-1/IL-36 inflammatory axis is a potent driver of disease pathology in GPP.
BACKGROUND: Generalized pustular psoriasis (GPP) is a rare, debilitating, and often life-threatening inflammatory disease characterized by episodic infiltration of neutrophils into the skin, pustule development, and systemic inflammation, which can manifest in the presence or absence of chronic plaque psoriasis (PV). Current treatments are unsatisfactory and warrant a better understanding of GPP pathogenesis. OBJECTIVE: We sought to understand better the disease mechanism of GPP to allow improved targeted therapies. METHODS: We performed a gene expression study on formalin-fixed paraffin-embedded GPP (n = 28) and PV (n = 12) lesional biopsies and healthy control (n = 20) skin. Differential gene expression was analyzed using gene ontology and enrichment analysis. Gene expression was validated with quantitative RT-PCR and immunohistochemistry, and a potential disease mechanism was investigated using primary human cell culture. RESULTS: Compared with healthy skin, GPP lesions yielded 479 and PV 854 differentially expressed genes, respectively, with 184 upregulated in both diseases. We detected significant contributions of IL-17A, TNF, IL-1, IL-36, and interferons in both diseases; although GPP lesions furnished higher IL-1 and IL-36 and lower IL-17A and IFN-γ mRNA expression than PV lesions did. We detected prominent IL-36 expression by keratinocytes proximal to neutrophilic pustules, and we show that both neutrophils and neutrophil proteases activate IL-36. Suggesting another mechanism regulating IL-36 activity, the protease inhibitors serpin A1 and A3, which inhibit elastase and cathepsin G, respectively, were upregulated in both diseases and inhibited activation of IL-36. CONCLUSIONS: Our data indicate sustained activation of IL-1 and IL-36 in GPP, inducing neutrophil chemokine expression, infiltration, and pustule formation, suggesting that the IL-1/IL-36 inflammatory axis is a potent driver of disease pathology in GPP.
Authors: Aravind Subramanian; Pablo Tamayo; Vamsi K Mootha; Sayan Mukherjee; Benjamin L Ebert; Michael A Gillette; Amanda Paulovich; Scott L Pomeroy; Todd R Golub; Eric S Lander; Jill P Mesirov Journal: Proc Natl Acad Sci U S A Date: 2005-09-30 Impact factor: 11.205
Authors: Andrew Johnston; Xianying Xing; Andrew M Guzman; MaryBeth Riblett; Candace M Loyd; Nicole L Ward; Christian Wohn; Errol P Prens; Frank Wang; Lisa E Maier; Sewon Kang; John J Voorhees; James T Elder; Johann E Gudjonsson Journal: J Immunol Date: 2011-01-17 Impact factor: 5.422
Authors: William R Swindell; Philip E Stuart; Mrinal K Sarkar; John J Voorhees; James T Elder; Andrew Johnston; Johann E Gudjonsson Journal: BMC Med Genomics Date: 2014-05-22 Impact factor: 3.063
Authors: Alexandra Taracanova; Irene Tsilioni; Pio Conti; Errol R Norwitz; Susan E Leeman; Theoharis C Theoharides Journal: Proc Natl Acad Sci U S A Date: 2018-09-19 Impact factor: 11.205
Authors: Garrett J Patrick; Haiyun Liu; Martin P Alphonse; Dustin A Dikeman; Christine Youn; Jack C Otterson; Yu Wang; Advaitaa Ravipati; Momina Mazhar; George Denny; Roger V Ortines; Emily Zhang; Robert J Miller; Carly A Dillen; Qi Liu; Sabrina J Nolan; Kristine Nguyen; LeeAnn Marcello; Danh C Do; Eric M Wier; Yan Zhang; Gary Caviness; Alexander C Klimowicz; Diane V Mierz; Jay S Fine; Guangping Sun; Raphaela Goldbach-Mansky; Alina I Marusina; Alexander A Merleev; Emanual Maverakis; Luis A Garza; Joshua D Milner; Peisong Gao; Meera Ramanujam; Ernest L Raymond; Nathan K Archer; Lloyd S Miller Journal: J Clin Invest Date: 2021-03-01 Impact factor: 14.808
Authors: Valentina Della Valle; Marco Maggioni; Carlo Carrera; Angelo Cattaneo; Angelo Valerio Marzano; Giovanni Damiani Journal: Intern Emerg Med Date: 2017-10-30 Impact factor: 3.397